Relative Strength in Biotech - BLTE(5/5) To highlight my point in the previous $VIVO post, here are 5 other charts in the Biotech sector that have shown relative strength lately. Don't get me wrong, the market is still on a downtrend, but should we reverse and start a new uptrend, this sector may potentially be the next one to lead a
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.18 USD
−36.14 M USD
0.00 USD
About Belite Bio, Inc
Sector
Industry
CEO
Yue Hsin Lin
Website
Headquarters
San Diego
Founded
2018
FIGI
BBG016LJYT18
Belite Bio, Inc. engages in the research and development of drugs. It focuses on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.